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Abstract: 
Antimicrobial resistance (AMR) is a growing public health threat worldwide occurring in a wide range of 
pathogenic bacteria. It is encouraging that governments of countries around the world are beginning to pay 
attention to the issue of AMR that serves to undermine the future of modern medicine. However, each country 
solution approaches to this issue will differ in terms of magnitude and response capacity. Madagascar is a low-
income country and one of the poorest countries in the world with poor environmental hygiene practices and 
easy availability of antimicrobial drugs without medical prescription. These particular contexts certainly 
influence the spread of multi-drug resistant bacteria. This review presents reported data on AMR from 2001 to 
2018 in Madagascar among the World Health Organization (WHO) priority human pathogens, and determined 
the scope and magnitude of the AMR problems in the particular context of this low-income country, which could 
help in formulating effective response strategies for control of AMRs in Madagascar.  
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Abstrait: 
La résistance aux antimicrobiens (RAM) est une menace croissante pour la santé publique dans le monde, qui 
se produit dans un large éventail de bactéries pathogènes. Il est encourageant de constater que les 
gouvernements des pays du monde commencent à prêter attention à la question de la RAM qui sert à saper 
l'avenir de la médecine moderne. Cependant, chaque approche de solution de pays à ce problème sera 
différente en termes d'ampleur et de capacité de réponse. Madagascar est un pays à faible revenu et l'un des 
pays les plus pauvres du monde avec de mauvaises pratiques d'hygiène environnementale et des médicaments 
antimicrobiens facilement disponibles sans prescription médicale. Ces contextes particuliers influencent 
certainement la propagation de bactéries multirésistantes. Cette revue présente les données rapportées sur la 
RAM de 2001 à 2018 à Madagascar parmi les agents pathogènes humains prioritaires de l'Organisation 
mondiale de la santé (OMS), et a déterminé la portée et l'ampleur des problèmes de RAM dans le contexte 
particulier de ce pays à faible revenu, ce qui pourrait aider à formuler des stratégies de réponse efficaces pour 
le contrôle des RAM à Madagascar. 
Mots-clés: Antimicrobiens, Madagascar, Multi-pharmacorésistance, Prévalence 
Introduction: 
 
 Antimicrobial resistance (AMR) is 
increasing worldwide and represents a major 
threat to public health (1). Indeed, in the 
European Union and the United States, 
antibiotic resistance is reported to cause over 
25,000 and 23,000 deaths per year respect- 




ively (2). In India, over 58,000 babies were 
reported to have died in one year as a result 
of infection caused by resistant bacteria 
passed from the mothers to babies (3). Thus, 
AMR is a worldwide concern and governments 
around the world are beginning to pay 
attention to this colossal issue. 
Madagascar is the fourth largest 
island in the world located in the Indian 
Ocean (IO) off the eastern coast of 
southern Africa and east of Mozambique. 
Malagasy population is estimated around 25 
million with various and mixed culture demise 
by Malayo-Indonesian, African and Arab 
ancestry. Living on an isolated island, 
Malagasy people are not sheltered from this 
AMR threat. Although no study has shown 
evidence that linked infectious disease death 
and antibiotic resistance, several studies 
report the presence of multi-drug resistant 
(MDR) bacteria in Malagasy community (4-7). 
 Recently, Gay et al., (4) reviewed the 
antimicrobial resistance in IO including 
Madagascar and pointed out the threatening 
presence of AMR in IO, although the report 
was to be interpreted with caution. However, 
particular context of each country that may 
constitute main factors contributing to the 
development of antibiotic resistance have not 
been addressed. For instance, Madagascar is 
a low-income country and one of the poorest 
countries in the world with poor 
environmental hygiene practices and high 
availability of antimicrobial drugs without 
medical prescription.    
 Tackling AMR progression surely 
represents a big challenge that needs deep 
context analysis and concerted efforts of local 
authorities and large panel of researchers in 
different areas of expertise. This review 
summarizes epidemiological knowledge and 
trends of AMR in Madagascar from 2001 to 
2018 focusing on WHO antibiotic-resistant 
"priority pathogens" for research and 
development (R & D) for new antibiotics (8). 
The particular socio-economic background of 
the country and the management of bacterial 




 We conducted a bibliographic search 
for relevant available articles obtained 
through match searches using Google Scholar 
and PubMed. Relevant information was 
obtained for phenotypic and genotypic 
profiles (if available) of resistance in bacteria 
defined as ‘critical’, ‘high’ and ‘medium 
priority’ by the WHO (Table 1). Related terms 
such as ‘prevalence’, ‘resistance’, ‘antimi- 
crobial’, ‘antibiotic’, ‘epidemiology’, ‘Madaga- 
scar’, ‘African’, and ‘Indian Ocean’ were also 
used to search for additional data.  
 We considered only strains isolated 
from humans and excluded strains from 
animals, food and food products. Considering 
the low rate of publication by Malagasy 
researchers, unpublished results presented in 
international congresses and seminars were 
included. However, data reported through 
national doctorate and/or master defenses 
(n=10) which were also referenced in Google 
results and/or Malagasy University websites 
were excluded. In total, 24 published articles 
and international congresses and seminars 










WHO ‘critical priority’ pathogens in 
Madagascar: 
Enterobacteriaceae: carbapenem - resistant; 
ESBL-producing   
 The primary cause of resistance 
among members of the family Entero- 
bacteriaceae is β-lactamase production. In 
recent years, β-lactamases have extensively 
diversified due to the extensive use of β-
lactams in hospitals (9). One of the most 
threatening β-lactamase is the extended-
spectrum β-lactamase (ESBL) which confers 
resistance in Enterobacteriaceae to β-lactam 
antibiotics and carbapenems, except to 
cephamycin, but inhibited by clavulanic acid 
(10).      
 In Madagascar, ESBL producing 
Enterobacteriaceae (ESBL-PE) was first 
isolated in urinary tract infections between 
2004 and 2006 (11). Following that period, 
high fecal carriage of ESBL-PE was identified 
in both community (Table 2) and hospitals 
(Table 3). For instance, a prevalence of 
21.3% was reported in two hospitals of 
Antananarivo from 2006 to 2008 (12). The 
same trend (21.2%) was reported in a 
pediatric hospital in 2008 (5) whereas 10.1% 
was reported by Herindrainy et al., (6) in 
community setting investigation in 2009. 
Between 2013 and 2014, 18.5% of rectal 
colonization by ESBL-PE was estimated 
among pregnant women at delivery (7). 
Another study conducted among patients, 
healthcare workers and students reported 
7.1% of Enterobacteriaceae nasal carriage 
resistance to third generation cephalosporin 
(3GC) in patients at admission (13). A study 
conducted in neonatal units of two different 
hospitals in Antananarivo from 2012 to 2013 
reported the presence of ESBL-PE in early 
neonatal infection (12.9%). Due to the lack 
of carbapenems, these infections were 
treated with extended spectrum cephalo- 
sporins resulting in high mortality rate of 
45% (14).     
 ESBL-PE in Madagascar mostly belong 
to the CTX-M-15 type (12,15) which is widely 
distributed worldwide (16), followed by SHV-
12 type, whereas one New Delhi metallo-β-
lactamase-1 (NDM-1)-producing Entero- 
bacteriaceae (Klebsiella pneumoniae) was 
isolated among pregnant women in the 
community (12). Additionally, the first 
carbapenem resistant Enterobacteriaceae 
(CRE) was reported in a community survey of 
uropathogens implemented in 2011–2013 
(17). Imipenem resistance rate was 40% for 
K. pneumoniae, 15% for Enterobacter 
cloacae and 2.3% for Escherichia coli. 
However, the small sample size for this study 
could not reflect global resistance patterns. 
Overall, 5.7% (871/15,100) of the population 
studied had ESBL-PE isolated. 
 





resistant    
 In Madagascar, the epidemiological 
situation of resistance of A. baumannii is 
difficult to estimate due to limited samples. 
In the first decade of this century (2006–
2008), a prevalence of A. baumannii of 8.8% 
was reported in infections diagnosed at 
hospital; the resistance to ceftazidime 
(62.0%) and imipenem was particularly high 
(45.7%) (9).     
 A study conducted by Andria- 
manantena et al., (18) among patients from 
four hospitals (three public and one private) 
in Antananarivo reported that 44% of 
collected strains between 2006 and 2009 
were resistant to imipenem and 94.3% to 
ceftazidime, with multi-drug resistant OXA-
23-producing A. baumannii phenotype, while 
no resistance to carbapenem was reported by 
Rasamiravaka et al., (17) among ten 
uropathogenic isolates in the community 
between 2011 and 2013.   
Pseudomonas aeruginosa: carbapenem- 
resistant    
 Data in regard of Pseudomonas is 
very rare as this strain is not commonly 
isolated from infected patients. In 2006-
2008, P. aeruginosa isolates showed 
moderate resistance to penicillins (piperacillin 
12.8% and ticarcillin 31.9%) but still 
susceptible to ceftazidime and imipenem (9).  
WHO ‘high and medium priority’ 
pathogens in Madagascar:                        
Staphylococcus aureus, methicillin-resistant, 
vancomycin-intermediate and resistant                                 
 In Madagascar, the prevalence of 
MRSA increased from 2001 to 2014 as shown 
in Table 4 and 5. Beginning from rates of 0 to 
6% in year 2000 and through the first decade 
of the twenty first century, nasal carriage 
rate of MRSA in the community increased to 
14.8% in 2011 (19, 20). Data collected by 
Andrianarivelo et al., (21) seems to corrob- 
orate the trend in community acquired as 
well as hospital acquired strains (13.8% and 
15.7% respectively). In most of the studies, 
risk factors analysis revealed that history of 
hospitalization, recent antibiotic intake and 
frequent contact with animals and livestock 
workers/veterinarians increase the risk of 
MRSA nasal carriage.    
 Indeed, populations constantly in 
contact with animals are the most MRSA 
carriers and this is particularly relevant 
among Malagasy pig and poultry farmers 
(25% of MRSA carrier, 45/180) (22). Overall, 
resistance rates were higher for widely 
available drugs (23). Increasing rate of 
resistance to gentamicin (42.9%) and 
vancomycin (7.1%) was observed in MRSA 
isolates (20). In the same line, an increase 
resistance rates to fluoroquinolones have 
been noticed (19-22). Considering all 
collected data, 3.1% (317/10,191) of studied 
populations have been in contact with MRSA 
strains.  
Enterococcus faecium, vancomycin-resistant 
 In Madagascar, reported data of 
Enterococcus-vancomycin resistant (EVR) are 
very poor. In 2006–2008, rate of resistance 
to vancomycin in Enterococcus spp. was 
3.3% (9) whereas in 2011–2013, one E. 
faecalis resistant to vancomycin (5.6%) was 
isolated during an uropathogenic survey (17). 
 






Salmonella spp., fluoroquinolone resistant 
 Salmonella spp. are major fecal–oral 
food-borne pathogens found worldwide. Most 
human salmonellosis is associated with eating 
contaminated raw or undercooked chicken, 
eggs, pork, and contaminated water. In 
Madagascar, resistance rates of community 
associated Salmonella spp. among children in 
2008–2009 was 0% for quinolones, low for 
3GC (1.2% for ceftazidime and cefotaxime) 
and moderate for ampicillin (35.7%) and 
ticarcillin (35.7%) (24). 
Campylobacter spp., fluoroquinolone resistant 
 Campylobacter spp. are responsible 
for both gastro-enteritis and extra-intestinal 
diseases in which C. jejuni and C. coli are the 
most isolated species from patients with 
diarrhea, as reported by Randremanana et 
al., (25) in their studies conducted between 
2010–2012 (70.1% and 23.6% respectively). 
The main source of infection in humans is 
cross-contamination from the environment 
including livestock animal contact and 
contamination from undercooked chicken, 
raw or unpasteurized milk (26). The rate of 
resistance in Campylobacter spp. was low in 
community children (from study conducted 
between 2008 and 2009) with overall 
resistance rate of 2.2% to ciprofloxacin (24) 
while Campylobacter spp. collected in 2005–
2006 from chicken neck skin presented 5.5% 
resistance rate to ciprofloxacin (27). 
Shigella spp., fluoroquinolone resistant 
 Shigella spp. are commonly isolated 
from stool of dysenteric patients, particularly 
in developing countries (28). In Madagascar, 
resistance in S. dysenteriae started being 
reported by the end of the 1980s (29). 




Indeed, 5 resistant strains to ampicillin, 
carbenicillin, streptomycin, chloramphenicol, 
tetracycline, sulphonamides and trimethoprim 
were isolated from Malagasy children in 
Tananarive and on the east coast of 
Madagascar between 1988 and 1989. In the 
first decade of the 21st century, high rates of 
resistance were reported for widely used 
drugs (for example 79.9% for trimethoprim-
sulfamethoxazole, 62.8% for amoxicillin and 
62.2% for ticarcillin) among strains isolated 
from community children but no resistance to 
ciprofloxacin was reported (24). 
Resistance in Neisseria gonorrhoeae, 
Haemophilus influenzae, Helicobacter pylori 
and Streptococcus pneumoniae 
 A multicenter study conducted 
between 2004 and 2006 reported 125 cases 
of Neisseria gonorrhoeae infection in 
Antananarivo (30). All tested strains were 
susceptible to cephalosporins and fluoro- 
quinolones. In the same way, a study 
conducted in three pediatric hospitals of 
Antananarivo from 1998 to 2000 assessing 
the role of Haemophilus influenzae meningitis 
in Antananarivo reported that among 160 
cases of meningitis, H. influenzae type b 
were isolated from 27 cases. Antimicrobial 
susceptibility testing revealed that 42%, 29% 
and 22% of H. influenzae strains were 
resistant to chloramphenicol, amoxicillin and 
gentamicin respectively with no resistance to 
3GC (31). Another study reported a preva- 
lence of H. influenzae B to be 43% among 
119 children with meningitis in the main 
hospitals of Antananarivo and no resistance 
to 3GC was observed (32). 
 Resistance to other high priority 
pathogens such as clarithromycin-resistance 
in Helicobacter pylori have not yet been 
reported probably due to the lack of isolated 
bacteria as they require special culture media 
and environmental conditions for growth. 
However, this is contrasting with the high 
seroprevalence of H. pylori infection of 36.2% 
and 82% among children and adult Malagasy 
population respectively (33,34). A case report 
communicated that patient infected by H. 
pylori present refractory profile to 
metronidazole and clarithromycin treatment, 
the first and second-line therapy against H. 
pylori infection. Authors underlined that 
susceptibility testing is overpriced for the 
concerned population (36). Likewise, only 
one study carried out in the main hospital in 
Antananarivo from 1998 to 2000 reported 
that all Streptococcus pneumoniae isolated 
from children with meningitis were sensitive 
to penicillin G (32) while S. pneumoniae was 
the first isolated bacteria pathogen (34-52%) 
responsible for meningitis in Madagascar (31, 
36).  
Discussion: 
 A glance at bacterial resistance in 
countries surrounding Madagascar revealed 
that MRSA rates are lower in Malagasy 
community compared to that of Mauritius and 
La reunion (38% and 13% respectively). 
Similarly, ESBL rate is estimated to be lower 
compared to Mauritius and La reunion (50% 
and 5.6% respectively) (4). However, the 
main AMR issues identified for Madagascar 
were ESBL and MRSA which is in agreement 
with their increase worldwide over the past 
decade (37). Nevertheless, the collected data 
should be interpreted with caution. Indeed, 
due to the diversity of study designs 
(diagnostic isolates versus systematic 
detection), antibiogram panels, different 
periods of time and sample collection, 
comparison of AMR patterns between 
territories may be difficult. This is one of the 
reasons we did not present meta-analysis 
and estimate the evolution of AMR in 
Malagasy community from 2001 to 2018. 
 Additionally, the studies were 
generally fractionated to limited population, 
for instance, all MRSA surveys were 
conducted in Antananarivo suggesting that 
the major population were natives of this 
town. However, healthcare facilities are very 
restricted in some regions such that people 
from rural areas go to urban city for care, 
suggesting that the studied populations may 
actually be from different areas of 
Madagascar. In any case, it is important to 
point out that data are concentrated in capital 
town of Madagascar. Indeed, if prevalence 
rate is lower in Antananarivo, it may be 
actually higher in the suburb and scrubland 
where access to water and healthcare 
facilities are lacking.    
 Only one study conducted in 14 
districts of Madagascar by Institute Pasteur of 
Madagascar investigated the presence of 
ESBL-PE in stool samples from pediatric 
population (24). A longitudinal survey that 
take account of the native town of 
investigated population and cover at least the 
capital town of each Malagasy region will be 
necessary to really appreciate the magnitude 
of AMR among Malagasy population. Another 
critical limitation of studies carried out in 
Madagascar is the lack of molecular typing. 
Only few studies, principally carried out by 
Institute Pasteur of Madagascar reported 
molecular data in a multicenter study. In 
most studies, the presence of mecA gene in 
isolated MRSA strains was not verified. This is 
also valid for ESBL-PEs where very few 
studies investigated their molecular typing. 
This limitation is principally due to high cost 
of molecular analysis and the implementation  




of PCR platform is difficult even in urban 
laboratory.     
 According to our academic 
experience, it is important to note that there 
are studies conducted by academic 
researchers which focused on AMR 
prevalence with phenotypic and genotypic 
profiles presented at doctorate and master 
defense. Regrettably, they have not yet been 
published in peer reviewed journals or 
communicated in international conferences 
due to the inability of local researchers to 
cover the publication fees (personal 
communication). Generally, they are able to 
publish their work only in association with 
international funders or academic institutes. 
This fact may explain the gaps in information 
on pathogens of major public health 
importance in Madagascar. However, it is 
encouraging to remark that some peer-
review journals propose to waive the charge 
for publication in low-income countries for the 
promotion of research.  
Socio-economic factors in relation to AMR in 
Madagascar   
 Madagascar is one of the poorest 
countries in the World. Indeed, more than 
three out of every four citizens of the country 
lived on less than $1.90 a day in 2019 (38). 
There is poor access to water, and sanitation 
and hygiene facilities are totally absent in 
some areas and only about 35% of the 
population has access to clean water. Access 
to sufficient and safe sanitation facilities is 
vital for hygiene, disease prevention, and 
human health. Although Madagascar has 
rainfall and water resources, they are under-
exploited and access to good drinking water 
is difficult even in the capital town of 
Madagascar (39,40).    
 The lack of access to water supply 
and sanitation has significant health impacts 
especially in propagation of infectious 
diseases and MDR organisms. In the same 
line, access to healthcare facility is difficult 
particularly in rural areas, where citizens 
have to walk over 20 miles on foot of rugged 
roads to reach the simplest healthcare facility 
where inadequate services are offered.  
Antibiotic consumption and AMR infections in 
Madagascar     
 A direct relationship between 
antibiotic consumption, emergence, and 
dissemination of AMR has been demonstrated 
(41). A study conducted by Padget et al., 
(42) reported that children population 
estimates for antibiotic consumption were 
29.3% in Antananarivo and 24.6% in 
Moramanga (a town 200 km from 
Antananarivo). In all investigated sites, the 
large majority of antibiotics were taken with 
prescription (92.2% and 87.0% for 
Antananarivo and Moramanga respectively) 
and purchased in pharmacies (89.4% and 
73.5% for Antananarivo and Moramanga 
respectively). Moreover, living in houses 
without modern toilets and age between 6 to 
18 months were significantly associated with 
antibiotic consumption after adjusting for 
sites, and a higher density of public health 
structures was associated with lower 
antibiotic consumption levels, while a higher 
density of private pharmacies was associated 
with higher levels across sites. Importantly, 
most of the antibiotics can be purchased 
without medical prescription and regulations 
on the prohibition of dispensing non-
prescription drugs exist only for particular 
cases (certain antibiotics) and particular 
period (e g. plague epidemic of 2017) (43).
 With regards to medical prescription, 
the physician role is based on the correct 
prescription of antibiotics although it is 
sometimes difficult to make an accurate 
diagnosis in low-income countries where 
diagnostic tools for bacterial infections are 
limited and only present in major cities. 
Furthermore, the risk of superinfection is high 
in localities where hygiene is very precarious 
and this context brings doctors to 
immediately establish antibiotic therapy even 
if they are aware of the viral origin of 
infection. Moreover, in rural localities, 
patients often travel more than 10 miles to 
reach a healthcare facility suggesting that 
patient who has received medication from the 
doctor will no longer return for follow up 
check as far as his condition does not really 
get worse. Aware of these different 
parameters and constraints, physicians 
generally opt for empirical antibiotic 
coverage.     
 The monitoring system for MDR 
bacteria is less well developed in Madagascar, 
mainly due to limited diagnostic infra- 
structures. Bacterial cultures are only taken 
after failure of empirical antibiotic therapy 
and the number of hospital infections is 
undoubtedly underestimated. This empiric 
antibiotic approach is dependent on local 
prevalence of bacteria species. Due to the 
lack of microbiological analysis, there is no 
national database for bacterial profiles of UTI 
or vaginal infections such that the European, 
and particularly French database, are used as 
guide for empirical therapy. Intriguingly, a 
study conducted by Rasamiravaka et al., (17) 
demonstrated that the bacterial profiles of 
UTI in Madagascar is not the same as 
presented by French recommendation. 
Indeed, there is an increase rate of Gram-
positive cocci of up to 34% causing UTI while 
it is usually in the range of 10% in the French 
database. This point may lead to failure of 
empiric antibiotic therapy approach by using 
inappropriate antibiotics. Meanwhile, it can 




also lead to increase antimicrobial resistance 
by selecting persistent or resistant bacteria. 
It is also important to note that although 
bacteriological analysis of UTI is important for 
diagnosis of bacterial infection and 
surveillance of bacterial susceptibility to 
common antibiotics, its systematic use is 
difficult to install because of high costs of 
reagents and consumables.  
Conclusion:  
This review highlights the prevalence 
of resistant strains, particularly the ESBL 
producers, which is far from negligible in 
Madagascar although the overall estimation is 
low. It seems necessary to set up strategy to 
monitor antibiotic resistance of greater 
magnitude. It is obvious that AMR spread is 
connected to the local socio-economic 
context indicating that tackling AMR spread 
does not fall only on physicians, pharmacists 
and microbiologists, but requires a high 
commitment of government with private 
partners in order to regulate antibiotic 
consumption, and improve healthcare 
facilities and hygiene access. Without radical 
improvement of accessibility and quality of 
healthcare as well as water, sanitation and 
hygiene facilities, the successful reduction of 
antibiotic resistance spread will remain 
utopian.     
 The main strategy should first focus 
on controlling the spread of resistant strains 
through; (i) proper use of antibiotics, (ii) 
training on the right prescription (national 
education in antibiotic use), and (iii) the fight 
against illicit sales. For antibiotics, they must 
be issued only under prescription. It is 
assumed that such measures will discourage 
self-medication which may decrease the 
number of customers of the pharmacists thus 
government supportive measures should be 
considered. Indeed, the government must 
reassure antibiotic distributors that 
prohibition of antibiotic delivery without 
prescription will have no negative impact in 
their business. Moreover, government should 
propose different measures to reduce 
distributors' fear such as subvention and/or 
drug tax reduction. These measures require 
the increase number of pharmacy and drug 
deposit to not damage the accessibility of the 
drug, which is virtually improved by their 
presence in grocery stores that are largely 
close to the population.   
 In parallel, accessibility to healthcare 
facilities should be improved and private 
pharmacies should be controlled in order to 
reduce antibiotic over consumption. Further- 
more, control of antibiotic dispatching as well 
as circulation/distribution of antibiotics should 
be rigorous to avoid the circulation of fake 
and poor-quality drugs. Indeed, some drugs 
placed on the market, despite having the 
active ingredients, may be under dosed or 
with poor bioavailability for the body resulting 
in decreased antibiotic concentration on the 
infectious sites. Such drugs must be tracked 
by the sanitary authorities. The free sale of 
authentic or non-genuine medication in 
general grocery stores must be prohibited, 
with only pharmacists and drug stores 
allowed to sell them. With regards to the 
difficulty of most Malagasy patients to pay for 
overpriced microbiological analysis due to 
high cost of reagents/consumables in medical 
laboratory, one alternative is the use of 
homemade reagents with the help of 
reference strains as quality control that may 
reduce charge of each test. For susceptibility 
testing, a proposed solution is to reduce the 
number of first line antibiotic disk testing to 
those really used by physicians and those 
detecting AMR. Thus, laboratory can propose 
cheaper price accessible to most households.
 Other important keys to prevent AMR 
are national and international network in 
surveillance of MDR strains. It is encouraging 
that the “Mérieux Foundation (MF)” supports 
the setting up of a laboratory network for 
medical microbiology analysis and infectious 
disease surveillance. With the support of the 
Ministry of Public Health, MF generates 
national laboratories network called 
RESAMED in order to standardize practices, 
facilitate the flow of data and knowledge, and 
participate in the national health strategy, 
particularly on antimicrobial resistance surv- 
eillance. However, this type of support should 
be extended to applied research such as 
discovery of new antimicrobial compounds 
and in a fundamental aspect including 
accurate microbiological resistance mechan- 
isms study. In this aspect, research and 
development (R & D) should be more 
innovative in the fight against bacterial 
infections by finding new original antibiotic 
with low risk of resistance from non-
cultivable and telluric bacteria or original 
antimicrobial compounds targeting virulence 
ability of bacteria instead of their viability. 
 This latter approach does not intend 
to compete with the search of new antibiotics 
or to replace the use of available antibiotics 
but rather to reduce the use of the latter (for 
example decrease the dose of prescribed 
antibiotic while maintaining its full 
effectiveness) which hopefully could slow 
down the spread of MDR bacteria. Other 
interesting compounds are those with 
antibiofilm properties. Indeed, the ability of 
bacteria to form biofilm is one of the key 
mechanisms of microbial resistance to 
antibiotics as the biofilm matrix protects 
them   against   antimicrobials   and  immune 




defense (44). It is promising that natural 
compounds have already been isolated from 
African and Malagasy plants with the ability 
to disrupt biofilm formation of Pseudomonas 
aeruginosa PAO1 and restore tobramycin 
effectiveness in in vitro experiments (45, 46).
 To conclude, Madagascar is not 
adequately armed to actively tackle MDR 
progression. It is urgent that the government 
adopt the minimal requirement to contain 
MDR progression such as increasing 
accessibility to health care service and 
prohibiting delivery of antibiotic without 
medical prescription. With the re-emergence 
of Plague in 2017 in the country, a very 
strong counterattack by the antimicrobial 
prophylaxis of mass was instituted by the 
health authorities (more than one million 
doses of antibiotic to treat 100,000 people 
were distributed by the WHO) so we can 
expect an increase in the resistance rate in 
the coming years. As evoked by WHO “While 
more R and D is vital, alone, it cannot solve 
the problem. To address resistance, there 
must also be better prevention of infections 
and appropriate use of existing antibiotics in 
humans and animals, as well as rational use 
of any new antibiotics that are developed in 
future…..The lack of adequate surveillance in 
many parts of the world leaves large gaps in 
existing knowledge of the distribution and 
extent of this phenomenon” (8).  
 This review article provides an update 
on the baseline data and enlightenment of 
the magnitude of AMR in Madagascar and the 
particular context of the country which may 
explain the difficulty in developing stand- 
ardized public health actions. Madagascar is 
under threat of AMR spread which needs 
urgent reaction of government and non-
governmental entities concerned in 
preservation of public health. 
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